ENGRAIL THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.engrail.com
A Dose-Response Safety Study of ENX-102 in Patients With GAD
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Engrail Therapeutics INC
- Target Recruit Count
- 36
- Registration Number
- NCT06653296
- Locations
- 🇬🇧
MAC Clinical Research, Manchester, United Kingdom
ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Phase 2
Recruiting
- Conditions
- Generalized Anxiety Disorder
- First Posted Date
- 2023-03-01
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Engrail Therapeutics INC
- Target Recruit Count
- 200
- Registration Number
- NCT05749055
ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Engrail Therapeutics INC
- Registration Number
- NCT05481905
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸University of Rochester, Rochester, New York, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
© Copyright 2025. All Rights Reserved by MedPath